Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
09/2005
09/21/2005CN1671395A Process for preparing water soluble phosphonooxymethyl derivatives of alcohol and phenol
09/21/2005CN1671391A Novel methods and compositions for alleviating pain
09/21/2005CN1671390A Adenosine A2A receptor antagonists for treating restless legs syndrome or related disorders
09/21/2005CN1671386A Substituted anilinic piperidines as MCH selective antagonists
09/21/2005CN1671378A Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy
09/21/2005CN1670183A Microbial L. rhamnosus GM-020 and its use for treating obesity
09/21/2005CN1670036A Chinese wolfberry polysaccharide extracting method and weight reduction product containing Chinese wolfberry polysaccharide
09/21/2005CN1670030A Preparation of privet total triterpenic acid extract and use thereof
09/21/2005CN1670009A Propynyl or dienyl biaromatic compounds
09/21/2005CN1669582A 胶原钙 Collagen calcium
09/21/2005CN1669575A Novel drug for treating cardiovascular and cerebrovascular diseases and process for preparing same
09/21/2005CN1669564A Traditional Chinese medicine preparation for treating cranial vascular diseases, its preparation method and application
09/21/2005CN1669558A Medicinal composition containing panax ginseng polysaccharide
09/21/2005CN1219780C Heterocyclic compounds binding chemotactic factor receptor
09/21/2005CN1219763C Substituted indole mannich bases
09/21/2005CN1219748C Solid compositions suitable for oral administration containing non-hydroscopic salts of L-carnitine and alkanoyl L-carnitines with taurine chloride and glycine chloride
09/21/2005CN1219548C Join of C peptide and insulin for treating diabetes complication and C peptide-specific antibody
09/21/2005CN1219546C Chinese medicine for reducing body weight and fat and its making method
09/21/2005CN1219534C Fat reducing anti-senility health product
09/21/2005CN1219523C Buccal lozenge of notoginseng flower
09/21/2005CN1219514C Oral medicine preparation with high absorbency
09/20/2005US6946579 3-carbocycle carbonyl-3-phenylpropionaldehyde intermediates and preparation by alkylating a carbocycle benzyl ketone with an allyl halide and oxidizing the product
09/20/2005US6946492 Use of C2-substituted indan-1-one systems for preparing medicaments for the treatment of obesity
09/20/2005US6946491 such as 3-[(4-(2-fluorobenzyloxy)phenyl)-methylthio]propionic acid; for treatment of insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis
09/20/2005US6946478 Compounds
09/20/2005US6946444 Modify the activity of the lipolysis stimulated receptor and can be used to influence the partitioning of dietary lipids between the liver and peripheral tissues; treating obesity-related insulin resistance
09/20/2005CA2345524C Combinations for diabetes which contain a sulfonylurea, a glitazone and a biguanide
09/15/2005WO2005085267A1 Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
09/15/2005WO2005085265A1 Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
09/15/2005WO2005085237A1 Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
09/15/2005WO2005085228A1 Cycloalkanopyridine derivative
09/15/2005WO2005085223A1 Composition for prevention and/or treatment of bone disease, functional food or health food containing the composition, and medicinal preparation containing the composition as active ingredient
09/15/2005WO2005085212A1 Substituted pyrimidine derivative
09/15/2005WO2005085210A1 Nitriles and medicinal compositions containing the same as the active ingredient
09/15/2005WO2005085200A1 Pyridone derivative
09/15/2005WO2005084697A1 Regulator for adiponectin receptor expression
09/15/2005WO2005084665A1 Niosome having metal porphyrin complex embedded therein, process for producing the same and drug with the use thereof
09/15/2005WO2005084463A1 Aggregates of eyeballs of crustaceans, usage, foods coataining the same, and production processes
09/15/2005WO2005025504A3 Modulators of calcitonin and amylin activity
09/15/2005WO2004100924A3 Method of preparing a formulation containing a microdosed active principle
09/15/2005US20050203284 a 15 to 22-residue polypeptide analog that forms an amphipathic alpha helix in the presence of lipids; anticholesterol agents; hypercholesterolemia, cardiovascular disorders, atherosclerosis, restenosis, hypertriglyceridemia, high density lipoprotein deficiency, metabolic disorders
09/15/2005US20050203186 Medicaments containing active ingredients which lower the level of cholesterol with time-delayed active ingredient release
09/15/2005US20050203158 Substituted benzimidazole compounds
09/15/2005US20050203154 Novel tetracyclic arylsulfonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them
09/15/2005US20050203126 Inhibitors of basic fibroblast growth factors (FGFs); treating cancer, rheumatoid arthritis, inflammatory bowel disease, cardiovascular disorders, diabetic retinopathy, achondroplasia, hypochondoplasia, or thanathophoric dysplasia
09/15/2005US20050203114 Pyrimidine-indole derivatives; cancer, autoimmunological, metabolic, inflammatory, infection (bacterial, viral, yeast, fungal, etc.), diseases of the central nervous system, degenerative neural disease, allergy/asthma, dermatology, angiogenesis, neovascularization, vasculogenesis, and cardiovascular
09/15/2005US20050203112 Bicyclic amides
09/15/2005US20050203109 Novel Compounds
09/15/2005US20050203093 Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4
09/15/2005US20050203071 Use of carbon-2-modified-19-nor-vitamin d analogs to induce the formation of new bone
09/15/2005US20050203066 Preventing mitochondrial respiratory chain dysfunction in mammal by administering a pyrimidine nucleotide precursor and pyruvic acid, ester or salt; neurodegenerative, muscular, urogenital, or developmental disorders; autism, neuropathic pain, headaches; anticarcinogenic agents; cognition activators
09/15/2005US20050203031 Useful for the treatment of type 2 diabetes, impaired glucose tolerance and certain other conditions
09/15/2005US20050203030 Novel effectors of dipeptidyl peptidase IV
09/15/2005US20050202548 Mammalian enzymatic polypeptide for use as tool in designing drugs which prevent and treat hypercholesterolemia, hyperlipemia, arteriosclerosis, parasitic infection, cell proliferative and vascular diseases
09/15/2005US20050202107 Use of ginkgo biloba extracts in order to promote muscle mass to the detriment of fatty mass
09/15/2005US20050202101 Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
09/15/2005US20050202032 Use of neglected target tissue antigens in modulation of immune responses
09/15/2005US20050202008 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
09/15/2005US20050201986 Cell targeting compositions and methods of using the same
09/15/2005US20050201962 Modified Porphyran
09/15/2005CA2558810A1 Methods for altering insulin secretion
09/15/2005CA2558274A1 Cycloalkanopyridine derivative
09/15/2005CA2558183A1 Use of enhanced water to improve blood sugar management
09/15/2005CA2557766A1 Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
09/15/2005CA2557320A1 Fused heterocyclic derivatives for prevention or treatment of hyperglycemia
09/15/2005CA2555050A1 8-[3-amino-piperidin-1-yl]-xanthine derivatives, the production thereof and the use in the form of a dpp-iv inhibitor
09/14/2005EP1574575A1 GLUCOSE AND/OR FRUCTOSE TRANSPORTER NaGLT1 AND ITS GENE
09/14/2005EP1574518A2 Venom-derived vascular endothelial growth factor-like protein having binding activity specific to vascular endothelial growth factor receptor type 2 and use thereof
09/14/2005EP1574219A2 Method of inhibiting fibrosis with a somatostatin agonist
09/14/2005EP1574214A1 Pharmaceutical composition comprising fenofibrate and process for its preparation
09/14/2005EP1573025A2 Crystallized structure of type iv collagen nc1 domain hexamer
09/14/2005EP1573003A2 Method for producing transgenic animals using oral gene therapy
09/14/2005EP1572995A2 Novel proteins and nucleic acids encoding same
09/14/2005EP1572934A2 Follistatin domain containing proteins
09/14/2005EP1572909A2 A follistatin domain containing protein
09/14/2005EP1572898A2 Novel proteins and nucleic acids encoding same
09/14/2005EP1572892A2 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
09/14/2005EP1572885A2 Methods for treating diabetes and other blood sugar disorders
09/14/2005EP1572881A2 Tacis and br3 polypeptides and uses thereof
09/14/2005EP1572877A2 Drug metabolizing enzymes
09/14/2005EP1572876A2 Transcriptional regulation of target genes
09/14/2005EP1572875A2 Receptors and membrane-associated proteins
09/14/2005EP1572863A2 Method for identifying inhibitors of g protein coupled receptor signaling
09/14/2005EP1572719A2 Partial peptide mimetics and methods
09/14/2005EP1572708A1 Novel fluoroglycoside heterocyclic derivatives, pharmaceutical products containing said compounds and the use thereof
09/14/2005EP1572707A1 Novel aromatic fluoroglycoside derivatives, pharmaceutical products containing said compounds and the use thereof
09/14/2005EP1572670A1 5-substituted-pyrazine or -pyridine glucokinase activators
09/14/2005EP1572660A1 Isoquinolinone derivatives and their use as therapeutic agents
09/14/2005EP1572638A2 An improved process for the preparation of amorphous atorvastatin calcium salt (2:1)
09/14/2005EP1572637A1 Novel mch receptor antagonists
09/14/2005EP1572243A1 Induction of tolerance through oral administration of a therapeutic agent coupled to a transporting agent
09/14/2005EP1572240A1 Compositions, methods, and kits useful for the alleviation of gastrointestinal side effects of lipase inhibitors
09/14/2005EP1572230A1 Placental alkaline phosphatase to control diabetes
09/14/2005EP1572227A2 Fwd, pp2c1, adk3, cg3860, cdk4, cg7134, eip75b involved in the regulation of energy homeostasis
09/14/2005EP1572203A1 Substituted 4-alkoxyoxazol derivatives as ppar agonists
09/14/2005EP1572198A2 New pharmaceutical compounds
09/14/2005EP1572196A1 Combination of a dpp-iv inhibitor and a ppar-alpha compound
09/14/2005EP1572185A1 Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents
09/14/2005EP1572180A1 USE OF a-PHENYLTHIOCARBOXYLIC AND a-PHENYLOXYCARBOXYLIC A CIDS WITH SERUM-GLUCOSE-LOWERING AND SERUM-LIPID-LOWERING ACTIVITY
09/14/2005EP1572129A2 Amidine derivatives for treating amyloidosis
1 ... 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 ... 1298